Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine

Pia Raanani, Ofer Shpilberg, Shmuel Gillis, Abraham Avigdor, Izhar Hardan, Miriam Berkowicz, Orit Sofer, Izidore Lossos, Angela Chetrit, Dina Ben-Yehuda, Isaac Ben-Bassat

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

We have assessed the outcome of 66 refractory and relapsed acute leukemia patients treated with high dose mitoxantrone and cytarabine. Therapy consisted of a total dose of 40-60 mg/m2 mitoxantrone and 3 g/m2 of cytarabine daily on 5 consecutive days. A total of 28 patients were treated for primary resistant and 38 patients for early or late relapsed leukemia. A total of 35 patients achieved CR. Four patients died during the induction course. Toxicity was acceptable and comparable to other salvage regimens. The median disease-free and overall survivals were 4 and 6 months, respectively. Although this regimen is effective in achieving remission in refractory leukemia, its duration is short.

Original languageEnglish (US)
Pages (from-to)695-700
Number of pages6
JournalLeukemia Research
Volume23
Issue number8
DOIs
StatePublished - Aug 1 1999
Externally publishedYes

Keywords

  • Acute leukemia
  • HIDAC
  • Mitoxantrone
  • Refractory
  • Relapsed
  • Salvage

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine'. Together they form a unique fingerprint.

  • Cite this

    Raanani, P., Shpilberg, O., Gillis, S., Avigdor, A., Hardan, I., Berkowicz, M., Sofer, O., Lossos, I., Chetrit, A., Ben-Yehuda, D., & Ben-Bassat, I. (1999). Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine. Leukemia Research, 23(8), 695-700. https://doi.org/10.1016/S0145-2126(99)00078-8